Contact this trialFirst, we need to learn more about you.
Integrase Inhibitor
Long-acting Cabotegravir + Rilpivirine for HIV
Recruiting2 awardsPhase 3
Fort Pierce, Florida
This trial is designed to compare the antiviral activity and safety of two regimens of an injectable combination of cabotegravir and rilpivirine given every 8 weeks or every 4 weeks, in adults living with HIV who are currently on a stable antiretroviral regimen.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service